Suchergebnisse - "Pesek, Milos"

PubPharm (90)

1

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC

enthalten in: Journal of Cancer | 2023

von Buresova, M. | Benesova, L. | Minarik, M. | +7

2

Combination of Circulating Tumour DNA and 18F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer : A Prospective Study

enthalten in: Cancer genomics & proteomics | 2022

von Fiala, O. | Baxa, J. | Svaton, M. | +9

3

Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis

enthalten in: Pathology oncology research : POR | 2022

von Benesova, L. | Ptackova, R. | Halkova, T. | +5

4

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

enthalten in: Anticancer research | 2021

von Skrickova, J. | Pesek, M. | Opalka, P. | +18

5

Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database

enthalten in: Genes, chromosomes & cancer | 2021

von Ptáková, N. | Martínek, P. | Holubec, L. | +11

6

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

enthalten in: Anticancer research | 2021

von Krejci, D. | Opalka, P. | Krejci, J. | +16

7

Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy

enthalten in: Anticancer research | 2021

von Svaton, M. | Blazek, J. | Krakorova, G. | +7

8

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer : A randomized, open-label, phase I/II trial

enthalten in: Cancer treatment and research communications | 2021

von Zemanova, M. | Cernovska, M. | Havel, L. | +20

9

Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy

enthalten in: Journal of Cancer | 2021

von Svaton, M. | Blazek, J. | Krakorova, G. | +6

10

Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients : Data from the Czech TULUNG Registry

enthalten in: Thoracic cancer | 2020

von Brat, K. | Bratova, M. | Skrickova, J. | +11

1
2
3
4
5
6
7
8
9
Nächster »
[9]